Skip to main content
61°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Brainstorm Cell
(NQ:
BCLI
)
1.200
-0.210 (-14.89%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Brainstorm Cell
< Previous
1
2
3
4
5
6
7
Next >
BCLI INVESTOR NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI
October 01, 2023
WHY: NEW YORK, NY - (NewMediaWire) - October 01, 2023 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
Via
TheNewswire.com
Exposures
Product Safety
BCLI INVESTOR NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI
October 01, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
Brainstorm Cell's Earnings: A Preview
August 11, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
September 28, 2023
Via
Benzinga
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation – BCLI
September 28, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Nasdaq Rises Over 100 Points; Accenture Shares Fall After Q4 Results
September 28, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 100 points on Thursday. The Dow traded up 0.40% to 33,683.43 while the NASDAQ rose 0.95% to 13,217.46. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
September 28, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
September 28, 2023
Via
Benzinga
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
September 28, 2023
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant...
Via
Benzinga
Crude Oil Moves Lower; CarMax Posts Downbeat Earnings
September 28, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining 1% on Thursday. The Dow traded up 0.58% to 33,745.23 while the NASDAQ rose 1% to 13,223.61. The S&P 500 also rose,...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
September 28, 2023
Via
Benzinga
Dow Rises 80 Points; US Jobless Claims Edge Higher
September 28, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining around 80 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 33,630.52 while the NASDAQ rose 0.12%...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 28, 2023
Via
Benzinga
FDA Advisory Panels Gives Thumbs Down To BrainStorm's Lead Therapy
September 28, 2023
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee meeting reviewing BrainStorm Cell Therapeutics Inc's (NASDAQ: BCLI) NurOwn application voted that NurOwn did not demonstrate substantial...
Via
Benzinga
Exposures
Product Safety
Why Galecto Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
September 27, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 26, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
September 25, 2023
Via
Benzinga
Gold Moves Lower; TransCode Therapeutics Shares Surge
September 25, 2023
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher by around 30 points on Monday. The Dow traded down 0.07% to 33,939.93 while the NASDAQ rose 0.24% to...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
September 25, 2023
Via
Benzinga
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
Nasdaq Turns Higher; SCYNEXIS Shares Plunge
September 25, 2023
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite trading higher on Monday. The Dow traded down 0.01% to 33,962.53 while the NASDAQ rose 0.26% to 13,246.15. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Neurodegenerative Disease-Focused Brainstorm Cell Therapeutics Stock Plunging Today?
September 25, 2023
Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) shares are sinking after the FDA released briefing documents ahead of the adcomm meeting scheduled on
Via
Benzinga
Exposures
Product Safety
U.S. Stocks Open Lower; Chicago Fed Index Falls In August
September 25, 2023
U.S. stocks traded mostly lower this morning, with the Dow Jones trading falling around 80 points on Monday. Following the market opening Monday, the Dow traded down 0.26% to 33,875.83 while the NASDAQ...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 25, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
September 25, 2023
It's time for another dive into the biggest pre-market stock movers as we check out all of the latest news on Monday morning!
Via
InvestorPlace
Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved"
September 14, 2023
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions...
Via
Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
July 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
BrainStorm Cell Therapeutics Shares Fall After Updated Biomarker Data From Lead Cell Therapy Candidate
July 07, 2023
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) presented new biomarker data from the Phase 3 trial of its late-stage investigational amyotrophic lateral sclerosis (ALS) treatment, NurOwn, at the 2023...
Via
Benzinga
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
July 06, 2023
BioRestorative Therapies Inc. (NASDAQ: BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumb
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.